Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 164.35.
Undervalued
The company’s latest PE is -0.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.91M shares, decreasing 0.56% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.73M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.46.